SiSaf Appoints Dr. Richard Goodfellow to Board of Directors

Guildford, England, 2 April 2023 – RNA delivery and therapeutics company SiSaf Ltd today announced that it has appointed Dr Richard Goodfellow to its Board of Directors.

Richard draws on four decades of international experience across the biotechnology and pharmaceutical sectors, including leadership roles in business development and as Chief Executive of Scancell, an AIM-listed clinical-stage immuno-oncology biopharmaceutical company. He has acted as a consultant to SiSaf since 2021.

SiSaf’s founder and CEO Dr Suzanne Saffie-Siebert said, “I’m delighted to welcome Richard to our Board. As we are building and expanding our commercial partnerships and in-house pipeline of RNA therapeutics, Richard’s vast range of experience in the life science industry will be a valuable addition to SiSaf’s board and will support the company’s further growth.”

Dr Richard Goodfellow commented on his appointment as Non-Executive Director, “I welcome the opportunity to join SiSaf’s Board. Having worked with Suzanne and her team in an advisory capacity for the past two years, I believe the potential of SiSaf’s next-generation delivery technology for life-changing RNA treatments is significant. I look forward to taking on a strategic role to help the company make the most of the opportunities this offers.”

SiSaf’s proprietary Bio-Courier technology addresses the limitations of other RNA delivery technologies through the hybridization of organic materials with inorganic bioabsorbable silicon. Its lead product SIS-101-ADO, an siRNA therapeutic for patients with Autosomal Dominant Osteopetrosis Type 2 (ADO2), a rare genetic skeletal disorder, began the U.S. FDA Regulatory process to obtain an Orphan Drug Designation in October 2022.